Related references
Note: Only part of the references are listed.Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy
Rita Bosetti et al.
NANOMEDICINE (2014)
Assessing the need for quality-adjusted cost-effectiveness studies of nanotechnological cancer therapies
Rita Bosetti et al.
NANOMEDICINE (2013)
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Nazila Kamaly et al.
CHEMICAL SOCIETY REVIEWS (2012)
The impact of effective patents on future innovations in nanomedicine
Rita Bosetti et al.
PHARMACEUTICAL PATENT ANALYST (2012)
Future of nanomedicine: obstacles and remedies
Rita Bosetti et al.
NANOMEDICINE (2011)
Decision-making in priority setting for medicines - A review of empirical studies
Lauri Vuorenkoski et al.
HEALTH POLICY (2008)
Multifunctional nanoparticles - properties and prospects for their use in human medicine
Nuria Sanvicens et al.
TRENDS IN BIOTECHNOLOGY (2008)
The carbon nanotube patent landscape in nanomedicine: an Expert opinion
Drew L. Harris et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2007)
The emerging nanomedicine landscape
Volker Wagner et al.
NATURE BIOTECHNOLOGY (2006)
Cost effectiveness analysis and the consistency of decision making - Evidence from pharmaceutical reimbursement in Australia (1991 to 1996)
B George et al.
PHARMACOECONOMICS (2001)
Share Paper
